Detalhe da pesquisa
1.
Germline risk of clonal haematopoiesis.
Nat Rev Genet
; 22(9): 603-617, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33986496
2.
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
Blood
; 2024 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38687605
3.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 403(10423): 249-260, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048786
4.
Interactive network-based clustering and investigation of multimorbidity association matrices with associationSubgraphs.
Bioinformatics
; 39(1)2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36472455
5.
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.
Blood
; 140(11): 1200-1228, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35767897
6.
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268448
7.
Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase.
Nat Chem Biol
; 18(4): 360-367, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34857958
8.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med
; 382(2): 140-151, 2020 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31914241
9.
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Blood
; 137(13): 1792-1803, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33024987
10.
TLR3 agonism augments CD47 inhibition in acute myeloid leukemia.
Haematologica
; 2023 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38152031
11.
Selective inhibition of MCL1 overcomes venetoclax resistance in a murine model of myelodysplastic syndromes.
Haematologica
; 108(2): 522-531, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35979721
12.
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Blood
; 136(6): 674-683, 2020 08 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32285126
13.
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.
Blood
; 136(2): 157-170, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32347921
14.
Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia.
Haematologica
; 107(4): 825-835, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33853293
15.
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.
BMC Cancer
; 22(1): 1013, 2022 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36153475
16.
Publisher Correction: Germline risk of clonal haematopoiesis.
Nat Rev Genet
; 22(9): 619, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34140664
17.
Increased Ripk1-mediated bone marrow necroptosis leads to myelodysplasia and bone marrow failure in mice.
Blood
; 133(2): 107-120, 2019 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413413
18.
The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5' and 3' ends of genes.
Nucleic Acids Res
; 47(8): 3921-3936, 2019 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30805632
19.
The evolving role of next generation sequencing in myelodysplastic syndromes.
Br J Haematol
; 188(2): 224-239, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31571207
20.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Blood
; 131(13): 1415-1424, 2018 03 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-29348128